SELE: E-selectin
Cell-surface glycoprotein having a role in immunoadhesion.
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on SELE, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
- Other 1
| Uproleselan | Phase 3 | Apollomics | Small molecule | AntagonistSelectin E antagonist | 2 |
| Rivipansel | Phase 3 | GlycoMimetics Incorporated | Small molecule | AntagonistSelectin E antagonist | 0 |
| CDP-850 | Phase 1 | — | Other | InhibitorSelectin E inhibitor | 0 |
| Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | Uproleselan | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | Dec 7, 2021 |
| Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | Uproleselan | Phase 2 / Phase 3 | Active, not recruiting | National Cancer Institute (NCI) | Oct 10, 2018 |
- Acute myeloid leukemia0.35
- Asthma0.28
- Acute myeloid leukemia by FAB classification0.26
- Deep vein thrombosis0.23
- Phlebitis0.17
- Thrombophlebitis0.16
- Autoimmune disorder of central nervous system0.16
- Varicose veins0.15
- Breast carcinoma0.12
- Neoplasm0.12
- Chronic obstructive pulmonary disease0.11
- Breast cancer0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3890, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P16581, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets